---
title: "U.S. stock market update: Klotho Neurosciences up 8.94%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247848897.md"
description: "Klotho Neurosciences rose 8.94%; ProKidney rose 60.66%, with a transaction volume of USD 788 million; Calidi Biotherapeutics rose 228.66%, with a transaction volume of USD 254 million; Abbvie fell 0.42%, with a transaction volume of USD 144 million, and a market capitalization of USD 333.8 billion"
datetime: "2025-07-09T14:22:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247848897.md)
  - [en](https://longbridge.com/en/news/247848897.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247848897.md)
generator: "portal-rs"
---

# U.S. stock market update: Klotho Neurosciences up 8.94%

**U.S. Stock Market Midday Update**

Klotho Neurosciences rose 8.94%. Based on recent important news:

1.  On June 10, Klotho Neurosciences announced that its licensed therapy showed potential in reducing age-related degeneration, causing the stock price to soar by 500%.

2.  On June 9, the active market in the innovative drug sector boosted sentiment in pharmaceutical stocks, with some individual stocks rising more than innovative drug companies.

3.  On June 4, Innovent Biologics released innovative pipeline data at the ASCO annual meeting, leading to a rise in stock price and boosting sentiment in related sectors.

**Stocks with High Trading Volume in the Industry**

Calidi Biotherapeutics rose 228.66%. According to recent key news:

1.  On July 8, Calidi Biotherapeutics published an editorial on NetworkNewsWire, increasing market attention and significantly driving up the stock price.

2.  On July 8, MTR Corporation signed an agreement for the Northern Link project with the government, which, although not directly related to Calidi, indicates market interest in infrastructure projects.

3.  On July 9, Daikin Heavy Industries released a profit forecast; despite a drop in its stock price, its profit growth shows the market's emphasis on high-value delivery.

Abbvie fell 0.42%, with increased trading volume. Based on recent important news:

1.  On July 9, analysts indicated that Abbvie was not on the recommended buy list, despite its rating being moderate buy, leading to a lack of market confidence and a 0.42% drop in stock price.

2.  On July 9, the innovative drug industry experienced high volatility, causing investors to hold a cautious attitude towards the industry's prospects, affecting Abbvie's stock price.

3.  On July 8, the application prospects of CAR-T cell therapy in autoimmune diseases attracted market attention, impacting the stock prices of related companies.

**Stocks with High Market Capitalization in the Industry**

Abbvie fell 0.42%, with increased trading volume. Based on recent important news:

1.  On July 9, analysts indicated that Abbvie was not on the recommended buy list, despite its rating being moderate buy, leading to a lack of market confidence and a 0.42% drop in stock price.

2.  On July 9, the innovative drug industry experienced high volatility, with investor biases affecting market sentiment, leading to stock price fluctuations.

3.  On July 9, the application prospects of CAR-T cell therapy in autoimmune diseases attracted market attention, but failed to boost Abbvie's stock price

### Related Stocks

- [KLTO.US](https://longbridge.com/en/quote/KLTO.US.md)
- [CLDI.US](https://longbridge.com/en/quote/CLDI.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [GRML.US](https://longbridge.com/en/quote/GRML.US.md)

## Related News & Research

- [Gold selloff pauses as US-Iran talks revive deal hopes. What to watch next?](https://longbridge.com/en/news/300396013.md)
- [AI’s $1 Trillion Funding Problem Is Moving From Stocks to Bonds](https://longbridge.com/en/news/300336501.md)
- [Micron or Nvidia: One AI Stock Is Poised to Outperform, the Other Is Harder to Call, Says Goldman Sachs](https://longbridge.com/en/news/300359724.md)
- [Nvidia’s CEO draws Pope Leo’s criticism as AI safety concerns surge 50%](https://longbridge.com/en/news/300379637.md)
- [SpaceX Stock Forecast: Valuation Is Hard to Justify, Says Top Investor](https://longbridge.com/en/news/300356131.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**